Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
TetraLogic Pharmaceuticals Corporation is a biotechnology firm focused on developing innovative therapies for cancer and viral diseases. The company is distinguished by its proprietary small molecule drug candidates, particularly in the area of apoptosis modulation, which targets specific pathways to induce cancer cell death. Its lead product candidate, birinapant, is designed to enhance the effectiveness of existing treatments in hematologic malignancies.
TetraLogic primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies for the development and commercialization of its drug candidates. The company holds a unique position in apoptosis modulation, which provides it with a competitive edge in targeting cancer therapies that are less saturated compared to traditional approaches.
Clinical trial results for birinapant, particularly in hematologic cancers
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from the FDA for its drug candidates
Market sentiment regarding the overall biotechnology sector
Regulatory changes impacting drug approval processes
Technological disruption in drug development methodologies
Emergence of alternative therapies that could outperform birinapant
Increased competition from larger biotech firms with more resources
High cash burn rate with no current revenue generation
Potential future dilution from equity financing
low - The biotechnology sector is generally less sensitive to economic cycles as healthcare spending is often considered essential.
Moderate - Rising interest rates could increase the cost of capital for TetraLogic, impacting its ability to fund ongoing clinical trials and operations.
minimal - The company has a low debt profile, which reduces its sensitivity to credit market conditions.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
high - The stock has exhibited extreme volatility, particularly with recent returns showing a 3900% increase over three months.